{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T21:22:52Z","timestamp":1780435372576,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"crossref","award":["2018YFC1705303"],"award-info":[{"award-number":["2018YFC1705303"]}],"id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Acute gouty arthritis (GA) is the main clinical manifestation and the most common initial symptom of gout. The treatment of acute GA involves the use of colchicine, non-steroidal anti-inflammatory drugs, and corticosteroids. Because of the side effects of these drugs, their clinical applications are limited. The use of traditional Chinese medicine for the treatment of acute GA has unique advantages. The aim of this trial is to clarify the treatment efficacy, safety, and recurrence control efficacy of\n                      <jats:italic>Huzhang<\/jats:italic>\n                      granules (HZG) in patients with GA showing dampness-heat syndrome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods\/design<\/jats:title>\n                    <jats:p>This double-blind, randomized, controlled trial was planned to be conducted between July 1, 2020, and December 31, 2022. A sample size of 267 participants (89 per group) with GA will be randomly assigned to three treatment groups in the ratio of 1:1:1: HZG, etoricoxib, and placebo groups. The study duration is 13\u2009days, including a 1-day screening period, 5-day intervention period, and 1-week follow-up period. The primary outcome is analgesic effectiveness, assessed as pain in the worst-affected joint, which will be measured using the visual analog scale. Secondary outcomes include the patient\u2019s assessment of pain in the primary study joint, patient\u2019s global assessment of response to therapy, investigator\u2019s global assessment of response to therapy, investigator\u2019s assessment of tenderness and swelling of the study joint, and TCM syndromes. Furthermore, the number, nature, and severity of adverse events will be recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study will provide evidence regarding the clinical efficacy and safety of Chinese medicine treatment for acute gouty arthritis. This study will provide noteworthy findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/register.clinicaltrials.gov\/\">NCT04462666<\/jats:ext-link>\n                      . Registered on July 05, 2020 (first version).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-022-06188-x","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T06:13:27Z","timestamp":1648793607000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Oral Huzhang granules for the treatment of acute gouty arthritis: protocol for a double-blind, randomized, controlled trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Mi","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-mei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2525-9679","authenticated-orcid":false,"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"issue":"1","key":"6188_CR1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/imr.12833","volume":"294","author":"G Cab\u0103u","year":"2020","unstructured":"Cab\u0103u G, Cri\u0219an TO, Kl\u00fcck V, Popp RA, Joosten LA. Urate-induced immune programming: consequences for gouty arthritis and hyperuricemia. Immunol Rev. 2020;294(1):92\u2013105.","journal-title":"Immunol Rev"},{"issue":"8","key":"6188_CR2","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1172\/JCI29404","volume":"116","author":"F Martinon","year":"2006","unstructured":"Martinon F, Glimcher LH. Gout: new insights into an old disease. J Clin Invest. 2006;116(8):2073\u20135.","journal-title":"J Clin Invest"},{"issue":"1","key":"6188_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-017-0922-5","volume":"15","author":"R Terkeltaub","year":"2017","unstructured":"Terkeltaub R. What makes gouty inflammation so variable? BMC Med. 2017;15(1):1\u201310.","journal-title":"BMC Med"},{"key":"6188_CR4","first-page":"971","volume":"9","author":"PP Khanna","year":"2015","unstructured":"Khanna PP, Shiozawa A, Walker V, Bancroft T, Essoi B, Akhras KS, et al. Health-related quality of life and treatment satisfaction in patients with gout: results from a cross-sectional study in a managed care setting. Patient Prefer Adherence. 2015;9:971.","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"6188_CR5","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/acr.22469","volume":"67","author":"SP Juraschek","year":"2015","unstructured":"Juraschek SP, Kovell LC, Miller ER III, Gelber AC. Gout, urate-lowering therapy, and uric acid levels among adults in the United States. Arthritis Care Res. 2015;67(4):588\u201392.","journal-title":"Arthritis Care Res"},{"issue":"11","key":"6188_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","volume":"11","author":"C-F Kuo","year":"2015","unstructured":"Kuo C-F, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649.","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"6188_CR7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/ncprheum0556","volume":"3","author":"E Roddy","year":"2007","unstructured":"Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol. 2007;3(8):443\u20139.","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"1","key":"6188_CR8","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12891-019-2519-y","volume":"20","author":"P Towiwat","year":"2019","unstructured":"Towiwat P, Chhana A, Dalbeth N. The anatomical pathology of gout: a systematic literature review. BMC Musculoskelet Disord. 2019;20(1):140.","journal-title":"BMC Musculoskelet Disord"},{"issue":"8","key":"6188_CR9","first-page":"906","volume":"36","author":"L Wilson","year":"2016","unstructured":"Wilson L, Saseen JJ. Gouty arthritis: a review of acute management and prevention. Pharmacotherapy: the journal of human pharmacology and drug. Therapy. 2016;36(8):906\u201322.","journal-title":"Therapy."},{"issue":"10","key":"6188_CR10","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1002\/art.27600","volume":"62","author":"A So","year":"2010","unstructured":"So A, De Meulemeester M, Pikhlak A, Y\u00fccel AE, Richard D, Murphy V, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 2010;62(10):3064\u201376.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"6188_CR11","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1136\/ard.2003.015743","volume":"63","author":"A Tausche","year":"2004","unstructured":"Tausche A, Richter K, Gr\u00e4ssler A, H\u00e4nsel S, Roch B, Schr\u00f6der H. Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor \u03b1 as a new therapeutic option. Ann Rheum Dis. 2004;63(10):1351\u20132.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"6188_CR12","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMcp1001124","volume":"364","author":"NT Gout","year":"2011","unstructured":"Gout NT. N Engl J Med. 2011;364(5):443\u201352.","journal-title":"N Engl J Med"},{"key":"6188_CR13","first-page":"1","volume":"2018","author":"N Xiao","year":"2018","unstructured":"Xiao N, Chen H, He S-Y, Xue C-X, Sui H, Chen J, et al. Evaluating the efficacy and adverse effects of clearing heat and removing dampness method of traditional Chinese medicine by comparison with western medicine in patients with gout. Evid Based Complement Alternat Med. 2018;2018:1\u201318.","journal-title":"Evid Based Complement Alternat Med"},{"key":"6188_CR14","first-page":"1","volume":"2020","author":"M Zhou","year":"2020","unstructured":"Zhou M, Ze K, Wang Y, Li X, Hua L, Lu Y, et al. Huzhang Tongfeng granule improves monosodium urate-induced inflammation of gouty arthritis rat model by downregulation of Cyr61 and related cytokines. Evid Based Complement Alternat Med. 2020;2020:1\u201313.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"1","key":"6188_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13020-020-0297-y","volume":"15","author":"X Chi","year":"2020","unstructured":"Chi X, Zhang H, Zhang S, Ma K. Chinese herbal medicine for gout: a review of the clinical evidence and pharmacological mechanisms. Chin Med. 2020;15(1):17.","journal-title":"Chin Med"},{"key":"6188_CR16","doi-asserted-by":"crossref","first-page":"6037037","DOI":"10.1155\/2017\/6037037","volume":"2017","author":"Y-F Liu","year":"2017","unstructured":"Liu Y-F, Huang Y, Wen C-Y-Z, Zhang J-J, Xing G-L, Tu S-H, et al. The effects of modified simiao decoction in the treatment of gouty arthritis: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2017;2017:6037037.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"4","key":"6188_CR17","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.27327","volume":"62","author":"RA Terkeltaub","year":"2010","unstructured":"Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett R, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four\u2013hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060\u20138.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"6188_CR18","first-page":"21","volume":"30","author":"L Yufei","year":"2018","unstructured":"Yufei L. Effects of Etoricoxib on primary acute severe gouty arthritis. Medi J Chinese People\u2019s Health. 2018;30(9):21\u20133.","journal-title":"Medi J Chinese People\u2019s Health"},{"issue":"5","key":"6188_CR19","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/0002-9343(68)90209-X","volume":"45","author":"AB Gutman","year":"1968","unstructured":"Gutman AB. Uric acid nephrolithiasis. Am J Med. 1968;45(5):756\u201379.","journal-title":"Am J Med"},{"issue":"8","key":"6188_CR20","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","volume":"116","author":"HK Choi","year":"2007","unstructured":"Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116(8):894\u2013900.","journal-title":"Circulation."},{"issue":"1","key":"6188_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13075-018-1558-3","volume":"20","author":"M Sun","year":"2018","unstructured":"Sun M, Vazquez AI, Reynolds RJ, Singh JA, Reeves M, Merriman TR, et al. Untangling the complex relationships between incident gout risk, serum urate, and its comorbidities. Arthritis Res Ther. 2018;20(1):90.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"6188_CR22","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","volume":"125","author":"Y Zhu","year":"2012","unstructured":"Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007\u20132008. Am J Med. 2012;125(7):679\u201387 e1.","journal-title":"Am J Med"},{"issue":"1","key":"6188_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-019-0115-y","volume":"5","author":"N Dalbeth","year":"2019","unstructured":"Dalbeth N, Choi HK, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F, et al. Gout. Nat Rev Dis Primers. 2019;5(1):69.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"6188_CR24","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.semarthrit.2017.09.007","volume":"47","author":"LE Scheepers","year":"2018","unstructured":"Scheepers LE, van Onna M, Stehouwer CD, Singh JA, Arts IC, Boonen A, et al. Medication adherence among patients with gout: a systematic review and meta-analysis. Semin Arthritis Rheum. 2018;47(5):689\u2013702.","journal-title":"Semin Arthritis Rheum"},{"key":"6188_CR25","doi-asserted-by":"crossref","unstructured":"Chua CKT, Cheung PP, Santosa A, Lim AYN, Teng GG. Burden and management of gout in a multi-ethnic Asian cohort. Rheumatol Int. 2020;40(7):1029\u201335.","DOI":"10.1007\/s00296-019-04475-6"},{"issue":"4","key":"6188_CR26","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3899\/jrheum.170806","volume":"45","author":"MM Elfishawi","year":"2018","unstructured":"Elfishawi MM, Zleik N, Kvrgic Z, Michet CJ, Crowson CS, Matteson EL, et al. The rising incidence of gout and the increasing burden of comorbidities: a population-based study over 20\u2009years. J Rheumatol. 2018;45(4):574\u20139.","journal-title":"J Rheumatol"},{"issue":"7","key":"6188_CR27","doi-asserted-by":"publisher","first-page":"A656","DOI":"10.1016\/j.jval.2015.09.2371","volume":"18","author":"C Neves","year":"2015","unstructured":"Neves C, Shields G, Beard S. A systematic review of the cost burden of gout. Value Health. 2015;18(7):A656.","journal-title":"Value Health"},{"issue":"4","key":"6188_CR28","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.semarthrit.2015.06.002","volume":"45","author":"B Spaetgens","year":"2016","unstructured":"Spaetgens B, Boonen A. The importance of \u2018state-of-the-art\u2019 cost-of-illness studies. Comment on: the economic burden of gout: a systematic review. Semin Arthritis Rheum. 2016;45(4):e9.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"6188_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11655-017-2826-9","volume":"24","author":"W-t Dang","year":"2018","unstructured":"Dang W-t, Xie W-g, Zhou J-g. Expression of PYCARD gene transcript variant mRNA in peripheral blood mononuclear cells of primary gout patients with different Chinese medicine syndromes. Chinese J Int Med. 2018;24(1):24\u201331.","journal-title":"Chinese J Int Med"},{"issue":"11","key":"6188_CR30","first-page":"992","volume":"26","author":"P Shao","year":"2006","unstructured":"Shao P, Huang X, Zjang F. Research on relationship of syndrome type and parameters of hemorheology and platelet activation in patients with acute gout arthritis of dampness-heat blockage type and stasis-heat accumulate type. Chinese J Int Traditional Western Med. 2006;26(11):992\u20134.","journal-title":"Chinese J Int Traditional Western Med"},{"issue":"33","key":"6188_CR31","first-page":"1591","volume":"04","author":"L Hua","year":"2018","unstructured":"Hua L, Zhou M, He Q-h, Zhao H-b, Tang J-y, Li X, et al. Effects of clearing heat and removing dampness and dredging collateral method on expression of NALP3 inflammasome in model of gouty arthritis rats. China J Traditional Chinese Med Pharm. 2018;04(33):1591\u20134.","journal-title":"China J Traditional Chinese Med Pharm"},{"issue":"10","key":"6188_CR32","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/acr.21773","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64(10):1447\u201361.","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06188-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06188-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06188-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T08:02:23Z","timestamp":1726905743000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06188-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6188"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06188-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-654229\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]},"assertion":[{"value":"10 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been reviewed and approved by the Institutional Ethics Committee of Shanghai Yueyang Integrated Medicine Hospital on May 14, 2020 (file number 2020\u2013024). This study is designed in accordance with the principles of the Declaration of Helsinki. All participants will provide written informed consent prior to enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing intersts.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"248"}}